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ABSTRACT
Aims Mutation detection accuracy has been described
extensively; however, it is surprising that pre-PCR
processing of formalin-ﬁxed parafﬁn-embedded (FFPE)
samples has not been systematically assessed in clinical
context. We designed a RING trial to (i) investigate pre-
PCR variability, (ii) correlate pre-PCR variation with
EGFR/BRAF mutation testing accuracy and (iii) investigate
causes for observed variation.
Methods 13 molecular pathology laboratories were
recruited. 104 blinded FFPE curls including engineered
FFPE curls, cell-negative FFPE curls and control FFPE
tissue samples were distributed to participants for pre-
PCR processing and mutation detection. Follow-up
analysis was performed to assess sample purity, DNA
integrity and DNA quantitation.
Results Rate of mutation detection failure was 11.9%.
Of these failures, 80% were attributed to pre-PCR error.
Signiﬁcant differences in DNA yields across all samples
were seen using analysis of variance (p<0.0001), and
yield variation from engineered samples was not
signiﬁcant (p=0.3782). Two laboratories failed DNA
extraction from samples that may be attributed to
operator error. DNA extraction protocols themselves were
not found to contribute signiﬁcant variation. 10/13 labs
reported yields averaging 235.8 ng (95% CI 90.7 to
380.9) from cell-negative samples, which was attributed
to issues with spectrophotometry. DNA measurements
using Qubit Fluorometry demonstrated a median ﬁvefold
overestimation of DNA quantity by Nanodrop
Spectrophotometry. DNA integrity and PCR inhibition
were factors not found to contribute signiﬁcant variation.
Conclusions In this study, we provide evidence
demonstrating that variation in pre-PCR steps is
prevalent and may detrimentally affect the patient’s
ability to receive critical therapy. We provide
recommendations for preanalytical workﬂow optimisation
that may reduce errors in down-stream sequencing and
for next-generation sequencing library generation.
INTRODUCTION
Use of epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor erlotinib as ﬁrst-line treat-
ment for non-small cell lung cancer (NSCLC) illus-
trates the potential for targeted drugs as
alternatives to chemotherapy.1–5 Initially, retro-
spective sequencing of tumours from responders
revealed activating EGFR mutations, making
tumour proﬁling a priority in NSCLC
management.6 Similarly, vemurafenib and BRAF
p.V600E have shaped workup of other cancers.7–9
This led to incremental improvements in PCR tech-
nology, culminating recently in PCR enrichment for
next-generation sequencing (NGS) library
making.10 Despite technical advances, assessing the
accuracy of pre-PCR steps, which include DNA
extraction from formalin-ﬁxed parafﬁn-embedded
(FFPE) tissues, DNA quantitation and DNA quality
control, remains a key challenge in external quality
assurance (EQA). Only two EQA programmes have
previously assessed DNA extraction and quantita-
tion in conjunction with downstream mutation
detection; however, both of these tested DNA
extraction from blood samples rather than FFPE.11
FFPE tissue preparation emerged 100 years ago
as a method for long-term tissue preservation.12
Today, mutation analysis from FFPE-derived DNA
assists diagnosis of most solid tumours. Formalin’s
use as a ﬁxative stems from its capacity for cross-
linking of proteins; however, it also forms bridges
between protein and nucleic acids, which can cause
impurities. Additionally, unbuffered formalin drives
acid-mediated hydrolytic nucleic acid fragmenta-
tion, which can inhibit PCR ampliﬁcation.13 DNA
extraction methods must therefore preserve nucleic
acid integrity while eliminating impurities.
Commercial DNA extraction kits typically
combine proteinase K digestion with solid-phase
DNA puriﬁcation. Variations in proteinase enzyme,
digestion time and incubation temperature exist
between methods.14
DNA quantitation may also impact PCR efﬁ-
ciency.15 Common methods include spectropho-
tometry, ﬂuorometry and qPCR. Nanodrop
spectrophotometry (Thermo Scientiﬁc, Waltham,
Massachusetts, USA) relies on light absorption by
DNA at 260 nm.16 Advantages include ease of use
and identifying contamination using absorbance
ratios. One disadvantage is that spectrophotometry
cannot differentiate DNA/RNA. Qubit Fluorometry
(Invitrogen, Carlsbad, California, USA) detects
ﬂuorescence from double-stranded DNA-speciﬁc
dyes but is more laborious. qPCR relies on quanti-
tation from the cycle threshold associated with a
template-speciﬁc probe. However, qPCR is the
most laborious and expensive of these methods.
Although the aforementioned variables have been
examined in isolation, their impact on downstream
mutation testing is unclear. To assess these variables
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in practice, we designed a diagnostic RING trial investigating
pre-PCR and mutation testing methods of 13 laboratories.
MATERIALS AND METHODS
Experimental design overview
Figure 1 provides a study overview. Thirteen laboratories (table 1)
were selected according to their workﬂow comprising either DNA
extraction or BRAF/EGFR mutation testing. Blinded FFPE
samples were analysed by participants. DNA extracts were
returned to University College London (UCL) for follow-up
analysis of purity, integrity and quantitation.
FFPE sample selection
To assess pre-PCR variation, engineered, cell-line FFPE curls
(Horizon Diagnostics, Cambridge, UK) were employed. SW48
and MCF10A cell lines were genetically modiﬁed to contain
clinically relevant EGFR and BRAF mutations using recombinant
adeno-associated virus vectors. The modiﬁed cell line was
titrated against its matched normal parental cell line to generate
mixtures containing quantiﬁable amounts of EGFR and BRAF
mutations. Cells were grown under standard tissue culture pro-
cedures, trypsin was used to release the cells and cells were
counted using a NC100 Nucleocounter (Chemometec,
Denmark). The cells were used to generate FFPE blocks manufac-
tured using a validated, proprietary method to achieve cell
numbers of 160 000 cells per FFPE section. Therefore,
each FFPE section contained deﬁned theoretical DNA yields
(see ﬁgure 1 for details). Cell numbers per section were validated
theoretically using known core and cell size. Section volume
(V=πr2h) was calculated as 15 mm * π * (2500 mm2)=294 375
000 mm3. SW48 and MCF10a cell volume (V=4/3πr3) was calcu-
lated as (4/3) * π * (7.5 mm3)=1766 mm3. The potential number
of cells comprising each 15 mm section is therefore 166 690 cells.
Consequently, the theoretical DNA yield of each 15 mm section is
1.1 mg assuming 6.6 pg DNA content in each cell (theoretical
DNA content in diploid cells). This is in accordance with
Horizon Diagnostics Aperio (Leica Biosystems, Denmark) cell
count data that measured cell numbers across 24 FFPE blocks,
demonstrating a mean cell count of 167 681 with an SD of
35 993. Additionally, comparison of DNA yields from 15 mm sec-
tions cut from 12 original FFPE blocks was performed by
Horizon Diagnostics. The Maxwell DNA extraction kit
(Promega, USA) was used to extract DNA from a total of 36
FFPE sections. DNA quantitation was performed using the
Figure 1 Overview of RING trial design. FFPE, formalin-ﬁxed parafﬁn-embedded; QFI, quantitative functional index; UCL, University College London.
112 Kapp JR, et al. J Clin Pathol 2015;68:111–118. doi:10.1136/jclinpath-2014-202644
Original article
group.bmj.com on December 7, 2015 - Published by http://jcp.bmj.com/Downloaded from 
Quantiﬂuor assay (Promega, USA). The mean DNA yield per
section was 465 ng with an SD of 94, which is in keeping with
the calculated theoretical yield. The allele ratios of mutations in
each sample were quantiﬁed using droplet digital PCR (ddPCR)
performed with the BioRad QX100 platform (Hercules,
California, USA).
Additionally, cell-negative FFPE curls and control FFPE tissue
were used as negative and positive extraction controls, respect-
ively. Thus, as shown in ﬁgure 1, each participant was sent the
following: six FFPE samples to assess pre-PCR steps that
included four curls with 1100 ng theoretical DNA yield, one
cell-negative curl and one curl comprising FFPE tonsil tissue.
Two FFPE samples to assess both pre-PCR steps and mutation
detection that included one curl with 1100 ng theoretical DNA
yield harbouring 25% BRAF V600E and 33% EGFR G719S,
and one curl with 1100 ng theoretical DNA yield harbouring
66% BRAF V600E and 20% EGFR L858R.
Sample preparation
Samples were blinded and labelled 1–8 (ﬁgure 1). Laboratories
were anonymised (A–M). Samples were shipped at room tem-
perature and stored at 5°C. One sample set was validated at
UCL using clinical protocols. DNA was extracted using the
QIAamp DNA FFPE tissue kit (Qiagen, Germantown,
Maryland, USA). DNA was quantiﬁed using Qubit V2.0
(Invitrogen, Carlsbad, USA). BRAF/EGFR screening was per-
formed using Sanger sequencing. Primer sequences are listed in
online supplementary table S1. Results were unblinded and con-
ﬁrmed against vendor speciﬁcations.
Participant instructions
Participants performed pre-PCR processing of samples 1–8,
recorded results and returned remaining DNA from samples 1
to 6 to UCL for follow-up. Participants screened samples 7 and
8 for EGFR/BRAF mutations. Laboratory directors signed the
data collection sheets provided.
Follow-up analysis
Follow-up analysis of DNA from samples 1 to 6 (n=78) includ-
ing quantitation, assessment of integrity and PCR inhibition was
performed at UCL and Asuragen.
QUANTITATION
Repeat DNA measurements (n=78) were performed at UCL and
Asuragen using a Qubit ﬂuorometer (Invitrogen). Qubit was
selected over qPCR due to its more frequent use alongside
Nanodrop.17 The Qubit dsDNA HS Assay Kit (Invitrogen) was
used for quantitation. Assay calibration was performed using the
internal controls provided. Measurements were correlated between
the two sites and compared with participants’ measurements.
DNA INTEGRITY
DNA integrity was assessed at UCL and Asuragen using inde-
pendent methods. Initial analysis was performed at UCL using a
Biomed2 multiplex-PCR assay of differently sized amplicons
(targeting 400, 300, 200 and 100 bp fragments of AFF1, PLZF,
RAG1 and TBXAS1, respectively), which enables visual analysis
of DNA fragment size distribution using a 6% polyacrylamide
gel.18 19 One microlitre of sample DNAwas used.
Asuragen assessed DNA integrity using quantitative functional
index (QFI)-PCR, which quantiﬁes the DNA templates that are
competent for PCR ampliﬁcation. This method measures the
fraction of ampliﬁable DNA in a sample by determining the
copy number of PCR-reportable DNA (referenced to a standard
curve of known copies of intact HapMap cell line DNA)
divided by the total number of bulk DNA copies (determined
Table 1 Overview of location, extraction method, quantitation method and mutation detection method for each laboratory
ID Country
Extraction
method
Quantitation
method
EGFR
detection method
BRAF
detection method
Lab A USA Manual silica matrix solid-phase purification (Qiagen
QIAamp)
Nanodrop Sanger sequencing
(in-house assay)
qPCR (in-house assay)
Lab B UK Automated silica matrix solid-phase purification (Qiagen EZ1) Nanodrop Pyrosequencing (in-house assay) Pyrosequencing (in-house assay)
Lab C USA Automated silica matrix solid-phase purification (Qiagen EZ1) Nanodrop Fragment analysis (in-house
assay)
qPCR (in-house assay)
Lab D UK Manual silica matrix solid-phase purification (LifeTech
RecoverAll)
Nanodrop NT Sanger sequencing (in-house
assay)
Lab E USA Manual silica matrix solid-phase purification (Qiagen DNeasy) Nanodrop NT NT
Lab F UK Manual silica matrix solid-phase purification (Roche COBAS) Nanodrop qPCR (Roche COBAS) qPCR (Roche COBAS)
Lab G USA Manual silica matrix solid-phase purification (Qiagen
QIAamp)
Nanodrop SNaPshot sequencing (in-house
assay)
qPCR (in-house assay)
Lab H USA Manual silica matrix solid-phase purification (Qiagen
QIAamp)
Nanodrop Sanger sequencing (in-house
assay)
Sanger sequencing
(in-house assay)
Lab I USA Manual silica matrix solid-phase purification (Qiagen
QIAamp)
Nanodrop qPCR (Qiagen Therascreen) Pyrosequencing
Lab J USA Manual silica matrix solid-phase purification (LifeTech
RecoverAll w/mods)
Nanodrop Massively paralleled
next-generation
sequencing (Ion Torrent PGM)
Massively paralleled next
generation
sequencing (Ion Torrent PGM)
Lab K UK Manual silica matrix solid-phase purification (Qiagen DNeasy) Nanodrop NT Pyrosequencing
Lab L UK Automated silica matrix solid-phase purification (Qiagen EZ1) Nanodrop Sanger sequencing Pyrosequencing
Lab M UK Manual silica matrix solid-phase purification (Qiagen
QIAamp)
Qubit Sanger sequencing Sanger sequencing
‘NT’ indicates the mutation in question was not routinely tested. Five laboratories were based in the UK and seven in the USA. The majority (12/13) were molecular pathology
laboratories associated with university hospitals. Laboratory J was a private laboratory based in the USA. Laboratory E did not perform routine epidermal growth factor receptor (EGFR)
or BRAF mutation testing but did perform DNA extraction from formalin-fixed paraffin-embedded. Laboratories D and K routinely screened for BRAF mutations but not EGFR mutations.
Laboratories C and G did not include the EGFR G719S mutation in their EGFR testing panel. The remaining laboratories routinely tested for both EGFR and BRAF mutations. DNA
extraction method varied though Qiagen products were favoured. Notably, DNA quantitation by Nanodrop spectrophotometry was used by all laboratories except for laboratory M,
which used Qubit Fluorometry. Mutation analysis was performed using a range of methods, of which Sanger sequencing and Pyrosequencing were the most common.
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by spectrophotometry). As demonstrated by Sah et al20, DNA
with low functional quality (and thus a low QFI score) is vulner-
able to false negatives and/or false positives in downstream
mutation assays.
PCR INHIBITION
The ‘SPUD’ qPCR assay was employed by Asuragen, which
benchmarks a reference Cq value generated from potato-speciﬁc
DNA against the Cq values generated for 1 mL of the study
samples.21 The original method was employed except that 600
copies of the potato-speciﬁc DNA target were used to provide
more sensitive detection of inhibition.
Statistical analysis
Multivariate statistical analysis including one-way analysis of
variance (ANOVA) (not assuming equal variances) was used to
assess pre-PCR variation. All statistical analyses were carried out
using R V2.14.2.
RESULTS
Participant demographics
The cohort comprised 13 clinical laboratories. Case volume of
each laboratory is illustrated in ﬁgure 2. Table 1 provides an
overview of participant methodology.
Variation in DNA recovery
The range of DNA recovery from the total number of samples
analysed in the ring trial (n=104) is shown in ﬁgure 3. Yield
variance was highest for (control) sample 6 (mean=4473.1 ng,
SD=5508.4 ng, CV=123.1%, n=13) and lowest for sample 2,
an engineered sample (mean=1016 ng, SD=1124.7 ng,
CV=58.4%, n=13). Signiﬁcant difference in DNA yields across
all samples was seen using ANOVA (p<0.0001); however, vari-
ation among engineered samples was not signiﬁcant
(p=0.3782). Consistency among the engineered samples was to
be expected due to their artiﬁcial nature, demonstrating their
suitability for use as reference material. On average, reported
yields from engineered samples (n=78) were 1.3-fold greater
than the calculated theoretical yield, suggesting potential pro-
blems arising during the pre-PCR process (see online supple-
mentary ﬁgure S1). Surprisingly, 10/13 laboratories reported
yields averaging 235.8 ng (SD=266.7, CV=1.13%, n=13) from
cell-negative sample 5.
Laboratory variation
Comparing DNA recovery from engineered samples shows
laboratory D was most consistent (CV=17.1%) and laboratory
K was least consistent (CV=146.7%) (see online supplementary
ﬁgure S2). Laboratory K failed DNA recovery from 7/8 samples.
Laboratory A failed DNA extraction from 2/8 samples.
Figure 2 Annual number of cases
screened by each participant for
epidermal growth factor receptor
(EGFR) and BRAF mutations
demonstrates that the cohort had
experience detecting EGFR and BRAF
mutations, on average screening >10
and >7 samples per week for EGFR
and BRAF mutations, respectively. The
volume of our cohort (489) is more
than double that of 112 participants in
a European external quality assurance
scheme, suggesting our ﬁndings may
be relevant to other laboratories.30
Figure 3 Range of total DNA (in
nanograms) recovered from each
sample by participants. In total, 104
samples were analysed. Samples 1–4
comprise theoretical DNA yields of
approximately 1100 ng, sample 5
comprises a cell-negative curl, sample
6 comprises a tonsil tissue specimen,
sample 7 comprises 1100 ng
theoretical DNA yield, in turn
harbouring BRAF V600E and EGFR
G719S, and sample 8 comprises
1100 ng theoretical DNA yield, in turn
harbouring BRAF V600E and EGFR
L858R. The range of DNA recovered
from the engineered samples, after
dropping laboratory K outlier values,
was >55-fold for two of the six and
>5-fold for the four others. Range in
DNA recovered from control sample 6,
excluding outliers from laboratory K,
was >40-fold.
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Mutation analysis
In total, 11.9% (5/42) of potential calls failed to detect the
EGFR or BRAF mutations present (table 2). Laboratory K failed
to detect mutations in samples 7 and 8 due to insufﬁcient DNA
recovery (two calls missed as did not routinely screen EGFR
mutations). Laboratory A failed to test sample 7 due to insufﬁ-
cient DNA recovery (two calls missed). Laboratory H extracted
adequate DNA but failed to detect 20% EGFR p.L858R in
sample 8 using Sanger sequencing (one call missed). This is
likely to be due to the limit of detection of Sanger sequencing
approaching 20% mutant: wild type.
Variation in pre-PCR steps
Extraction: Quantities of DNA extracted from the engineered
samples (measured by Qubit) were compared with respect to the
various extraction methodologies employed. The results demon-
strate that Qiagen EZ1 had the lowest yield variance
(CV=52%), while Qiagen QIAamp had the highest (CV=82%).
Despite small sample size, overall yield variance between the
methods was relatively low (30%) (ﬁgure 4).
Quantitation: Correlation between Nanodrop and Qubit
measurements for identical samples (n=78) was poor (R2=0.48,
p<0.0001) (see online supplementary ﬁgure S3). Comparing
Qubit versus Nanodrop measurements for identical samples,
represented as the Nanodrop:Qubit (N/Q) ratio, demonstrates
median Nanodrop readings were 5.1-fold higher than Qubit
measurements for the same samples (ﬁgure 5). In addition,
Qubit measurements of cell-negative sample 5 from all labora-
tories were undetectable in all cases.
DNA integrity: Sample quality (n=78) assessed using
multiplex-PCR showed degradation of DNA from control
sample 6 (ﬁgure 6C). In contrast, DNA from the engineered
samples was intact (ﬁgure 6A). Analysis of cell-negative sample 5
conﬁrmed absence of ampliﬁable material (ﬁgure 6B), underscor-
ing the signiﬁcance of DNA recovery reported for these samples.
Average N/Q ratio for the degraded control samples (N/Q=15.6)
was higher than intact engineered samples (N/Q=10.9).
Asuragen assessed samples from a subset of laboratories (D,
H, J, L and M) using QFI-PCR, which demonstrated DNA from
engineered samples 1–4 to have similar ‘functional’ quality, with
approximately 1 in 4–6 input templates ampliﬁed.20 In contrast,
<1 in 100 templates in DNA from control sample 6 were amp-
liﬁed. These ﬁndings have close correlation with the
multiplex-PCR data.
PCR inhibition: ‘SPUD’ PCR analysis demonstrates absence of
PCR inhibitors in all but one sample. Mean Cq across all
samples (Cq=30.21) was consistent with mean Cq from the
standard curve for 600 copies of exogenous DNA target
(Cq=30.14) in all but one sample, M6 (see online supplemen-
tary ﬁgure S4).
DISCUSSION
Recent EQA in NSCLC demonstrates suboptimal EGFR testing.22
Since EQA programmes assessing mutation detection from FFPE
samples do not usually assess pre-PCR steps, it is difﬁcult to estab-
lish causes of error. Although previous studies have assessed indi-
vidual pre-PCR steps such as DNA extraction from FFPE,23 24
accuracy of DNA quantitation15 17 23 25 26 27 and PCR inhib-
ition,28 29 this is the ﬁrst study, to the best of our knowledge, that
has compared both pre-PCR processing and mutation detection
from FFPE samples across different laboratories.
Table 2 Overview of mutation detection performance of each laboratory
Lab A Lab B Lab C Lab D Lab E Lab F Lab G Lab H Lab I Lab J Lab K Lab L Lab M
EGFR
Detection Method
Sanger Pyrosequencing qPCR NT NT qPCR qPCR Sanger qPCR NGS NT Sanger Sanger
BRAF
Detection Method
qPCR Pyrosequencing qPCR Sanger NT qPCR qPCR Sanger Pyrosequencing NGS Pyrosequencing Pyrosequencing Sanger
Specimen 7
EGFR exon 18
(33% G719S)
No Yes NT NT NT Yes NT Yes Yes Yes NT Yes Yes
BRAF exon 15
(25% V600E)
No Yes Yes Yes NT Yes Yes Yes Yes Yes No Yes Yes
Specimen 8
EGFR exon 21
(20% L858R)
Yes Yes Yes NT NT Yes Yes No Yes Yes NT Yes Yes
BRAF exon 15
(66% V600E)
Yes Yes Yes Yes NT Yes Yes Yes Yes Yes No Yes Yes
Total score 2/4 4/4 3/3 2/2 NT 4/4 3/3 3/4 4/4 4/4 0/2 4/4 4/4
Total number of potential calls=42. Total number of missed calls=5. Failure rate 5/42=11.9%. Laboratories were not assessed for mutations that they did not routinely provide
clinical screening.
NGS, next-generation sequencing; NT, not tested, denotes those mutations that laboratories did not routinely screen; EGFR, epidermal growth factor receptor.
Figure 4 Variance in DNA recovered by the different extraction
methods was calculated using Qubit measurements for engineered
samples 1–4. It should be noted that one of the laboratories used a
modiﬁed version of RecoverAll; however, for the purpose of the
analysis, these were treated the same. N refers to the number of
laboratories using each method.
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In this study, we systematically assessed pre-PCR steps
through a RING trial. Reported DNA yields from artiﬁcial
FFPE samples exceeded the calculated theoretical yields, sug-
gesting the possibility of discrepancies associated with pre-PCR
sample processing. The likelihood of this was increased because
the majority of participants reported large quantities of DNA
from cell-negative samples. Additionally, mutation detection
across the cohort was suboptimal. The majority of missed calls
(4/5) were caused by insufﬁcient DNA recovery from the engi-
neered samples. Therefore, we discuss some of the important
pre-PCR variables and potential solutions laboratories may
adopt to reduce variation in their methods.
DNA extraction methods are comparable
Basic criteria for DNA extraction methods include sufﬁcient DNA
extraction for analytical testing, removal of contaminants and pres-
ervation of DNA integrity. Lack of PCR inhibition, as shown by the
SPUD assay, in all but one sample indicates the methods employed
by the cohort are good at removing contaminants. Similarly, DNA
from the engineered samples remained intact, suggesting the
methods preserved DNA quality. Considering that other partici-
pants consistently recovered DNA from all engineered samples, it is
not clear why laboratories A and K failed DNA extraction.
Laboratory K had the lowest throughput (50/year) and may not
have had sufﬁcient operator experience. Therefore, operator error
may have led to failure to recover DNA from the samples.
However, laboratory A, which screens >1000 cases per year, had
more experience and yet failed DNA recovery from two samples
demonstrating that experience alone was insufﬁcient to guarantee
reliable DNA extraction. Overall, comparable DNA quality and
quantity (ΔCV=30%) was achieved by the different methods,
which suggests that differences in FFPE extraction kit are unlikely
to contribute signiﬁcant variation to the pre-PCR process.
However, failed DNA recovery by two laboratories indicates that
Figure 5 Average Nanodrop:Qubit
ratio for each laboratory as well as the
average and median ratio for the entire
cohort.
Figure 6 Biomed 2 multiplex PCR results for assessing DNA integrity. (A) Representative set of engineered samples indicates high-quality DNA
with four strong bands at 400, 300, 200 and 100 bp. (B) Comparison between engineered samples (B2 and C2) and a representative set of
cell-negative samples 5. No bands were seen for cell-negative samples except in samples from laboratories E, I and K. These were not reproducible
on repeat. (C) Representative set of control samples from each laboratory shows just one band at 100 bp indicating degraded DNA.
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operator error may be prevalent. Minimum variance associated
with the automated Qiagen EZ1 could reﬂect automated platforms
being less prone to operator variability. This is supported by the
fact that laboratories employing automated extraction methods (B,
C and L) experienced no failures. Therefore, use of automated plat-
forms may reduce operator error. In cases where throughput does
not justify automation, use of FFPE extraction controls may help
identify instances of DNA extraction failure.
Nanodrop overestimates DNA quantity
DNA quantitation is important because sequencing assays
cannot detect low abundance mutations if the minimum number of
mutant templates is not available. Almost all participants (12/13)
employed DNA quantitation using Nanodrop. This is unsurpris-
ing considering Nanodrop’s speed and low cost. All laboratories
employing Nanodrop, except laboratory E, reported DNA
recovery without interpretation of absorbance ratios, which was
surprising since they also used DNA extraction methods that
co-purify DNA/RNA.
Comparing Nanodrop and Qubit measurements of identical
samples (n=78) shows that Nanodrop overestimates DNA ﬁve-
fold, which could theoretically result in using lower amounts of
starting DNA for the downstream sequencing step and cause false
negative results. Discrepancies between the two methods were to
be expected since Deben et al,25 O’Neill et al27 and Simbolo
et al17 reported similar ﬁndings. However, Foley et al23 and
Haque et al26 provide contradictory reports. Therefore, our evi-
dence further supports discordance between the two. Considering
that Nanodrop is not DNA-speciﬁc and that laboratories used pro-
tocols for DNA/RNA co-puriﬁcation, discordance due to RNA
contamination is likely. However, it does not explain why yields
(average=235 ng) were reported for cell-negative samples using
Nanodrop. Factors such as DNA fragmentation have been asso-
ciated with higher Nanodrop readings. For example, Simbolo et al
report worse Qubit/Nanodrop correlation for partially degraded
versus intact DNA.17 This was conﬁrmed in our study, which
showed the N/Q ratio was higher for degraded control samples
than intact engineered samples. Deben et al25 investigated RNA
extraction from FFPE and found that Nanodrop measurements
were 32% higher than Qubit. However, when measuring RNA
extracted from non-FFPE material, they found both methods to be
similar. Foley et al23 also demonstrated concordance measuring
non-FFPE samples. Although these published ﬁndings may
reﬂect the effects of formalin-induced fragmentation, we
propose that incomplete parafﬁn removal may also contribute
to artiﬁcially raised Nanodrop measurements. Although sample
contamination was not evident from the SPUD assay results, it
is conceivable that the contaminant may only confound ultra-
violet light absorbance and have little impact on ampliﬁcation
efﬁciency. Other factors that may contribute variation to
Nanodrop include using less than recommended sample size
that can result in incomplete formation of the liquid sample
column. Additionally, if the reference/blank solution is not
identical to the sample solvent or if the blank sample is not
measured ﬁrst, inaccurate quantitation may occur. However,
these factors alone cannot be responsible for the degree of vari-
ation observed between Nanodrop and Qubit, nor the discrep-
ancies associated with the blank samples.
Reported DNA yield from cell-negative samples underlines
the importance of interpreting Nanodrop results using absorb-
ance ratios. Good quality DNA should have 260/280 nm ratios
between 1.7 and 2.0, while 260/280 ratios >2 indicate RNA
contamination.26 When using protocols co-purifying DNA/
RNA, laboratories should use Qubit or qPCR for DNA
quantitation because Nanodrop is not DNA speciﬁc. Employing
cell-negative controls and commercial gDNA may improve
quantitation accuracy. Simbolo et al17 recommend concomitant
use of Nanodrop (for measuring sample purity) and Qubit (for
accurate DNA quantitation), which offers the most reliable
protocol with optimal cost/time requirements.
Measurement of DNA integrity is a useful addition to the
pre-PCR process
Extraction methods cannot efﬁciently purify DNA fragments
<100 bp.14 If a given sample does not contain the required
number of mutant templates, downstream mutation detection
will not be successful. Measuring DNA integrity during
pre-PCR may therefore save costs and time. We demonstrated
use of QFI-PCR for assessing DNA integrity, which quantiﬁes
the percentage of templates competent for ampliﬁcation.20
Alternatively, the BIOMED2 multiplex-PCR assay enables ana-
lysis of the distribution of varying DNA fragment sizes.
CONCLUSION
In this study, we demonstrate that while mutation detection
assays are seen to be reliable, failures in DNA extraction are
prevalent. Such failures in DNA recovery represent a waste of
precious patient samples, which necessitates repeat testing or
even repeat biopsy that can delay critical patient therapy. In add-
ition, we have demonstrated that signiﬁcant variation exists
between DNA quantitation protocols that might cause laborator-
ies to overestimate the quantity of DNA in their samples.
Operator error may account for failures observed in manual
DNA extraction and may be reduced using automated methods
such as Qiagen EZ1, or in manual instances, by incorporating
DNA extraction controls. DNA quantitation in conjunction with
DNA/RNA co-puriﬁcation should be performed using Qubit or
qPCR since Nanodrop cannot distinguish DNA/RNA. However,
Nanodrop absorbance ratios should be used initially to assess
contamination. DNA integrity impacts ampliﬁcation efﬁciency
and should therefore be assessed during pre-PCR. We recom-
mend adaptations to the pre-PCR workﬂow that may help
laboratories reduce variation in their preanalytical process.
These adaptations are useful for laboratories carrying out
sample preparation for sequencing or for NGS library gener-
ation. We also recommend that assessment of pre-PCR process-
ing of FFPE samples be incorporated into EQA programmes. In
the design of this RING trial, we have demonstrated a model
for robust assessment of key pre-PCR components.
Take home messages
▸ Pre-PCR variation is signiﬁcant among experienced
laboratories, while down-stream EGFR and BRAF mutation
analysis is shown to be relatively robust.
▸ DNA extraction methods used in this study are comparable;
however, operator error may have led to failed DNA recovery
even in experienced laboratories with high case load.
▸ Nanodrop overestimates FFPE DNA compared to Qubit.
Qubit or qPCR should be the primary quantitation method,
particularly for protocols co-purifying DNA and RNA.
▸ External quality assurance programmes should include
pre-PCR steps in their assessment of mutation detection
from FFPE samples.
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